Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned ...

This was the stock's second consecutive day of losses.

Despite Quest Diagnostics’ strong performance, analysts remain cautiously optimistic about its prospects. The stock has a consensus rating of “Moderate Buy” from the 16 analysts covering the ...

Quest Diagnostics Incorporated price-eps-surprise | Quest Diagnostics Incorporated Quote Quest Diagnostics’ string of acquisitions is also expected to have bolstered its performance in the to-be ...

Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET ...

Quest's robust performance, alongside its collaboration ... or dementia. Quest Diagnostics is Thursday's IBD Stock Of The Day. Shares are lingering in a buy zone, helped by a Texas court's ruling.

Grail shares are trading higher Wednesday after the company announced a new collaboration with Quest Diagnostics aimed at improving provider access to its Galleri multi-cancer early detection test.

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Quest Diagnostics (NYSE:DGX ... Street estimates EPS to be $9.71 per share and revenue to be $10.78B. The stock is down 4% in early trading.

Assess today's live Quest Diagnostics orporated (DGX) share price, performance and insights using our live NYSE: DGX stock exchange data. Analyse the historical data and Quest Diagnostics orporated ...

Shares of Quest Diagnostics Inc. DGX slid 2.74% to $159.80 Tuesday, on what proved to be an all-around dismal trading session ...